You need to be logged in in order to compare forms with one another.
Displaying Form 1 - 30 of 226 in total



! '← Previous' 1 3 4 5 6 7 8

Rating Forms Actions
  • Global rating average: 4.0 out of 5
  • 4.0
  • 4.0
  • 4.0
  • 4.0
  • 4.0
NCI Standard Adverse Event/Serious Adverse Event CTCAE v3 Template - 2748814v1.0
version 5, 2015-02-04
  • Global rating average: 3.0 out of 5
  • 3.0
  • 3.0
  • 3.0
  • 3.0
  • 3.0
Breast Cancer Adverse Event NCT00382070
version 6, 2015-04-01
  • Global rating average: 3.0 out of 5
  • 3.0
  • 3.0
  • 3.0
  • 3.0
  • 3.0
CDASH Adverse Event
version 2, 2014-03-29
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Adverse Events Weeks 5- 7 Mepolizumab HES NCT00086658
version 1, today
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B (Visit 17 Year 11)
version 1, 2017-06-26
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B (Visit 19 Year 13)
version 1, 2017-06-26
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B (Visit 20 Year 14)
version 1, 2017-06-26
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
NON-SERIOUS ADVERSE EVENT REPORTING (DAY 0 - MONTH 12) CRFs Roche FVF4168G Macular Edema NCT00473330
version 2, 2017-06-25
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
NON-SERIOUS ADVERSE EVENT REPORTING (DAY 0 - MONTH 12) INVESTIGATOR / SITE INFORMATION (SCREENING) CRFs Roche FVF4170G Macular Edema NCT-Nummer: NCT00473382
version 1, 2017-06-25
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
SERIOUS / NON-SERIOUS EXPEDITED ADVERSE EVENT REPORTING (DAY 0 - MONTH 36) CRFs Roche FVF4168G Macular Edema NCT00473330
version 1, 2017-06-25
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
SERIOUS / NON-SERIOUS EXPEDITED ADVERSE EVENT REPORTING (DAY 0 - MONTH 36) CRFs Roche FVF4170G Macular Edema NCT00473382
version 1, 2017-06-25
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
NON-SERIOUS ADVERSE EVENT REPORTING (MONTH 13 - MONTH 24) CRFs Roche FVF4168G Macular Edema NCT00473330
version 2, 2017-06-25
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
NON-SERIOUS ADVERSE EVENT REPORTING (MONTH 13 - MONTH 24) CRFs Roche FVF4170G Macular Edema NCT00473382
version 1, 2017-06-25
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Serious Adverse Event: GSK DTPa vaccine (Infanrix) 100484
version 1, 2017-06-20
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Non-Serious Adverse Events - GSK Milveterol COPD 100527
version 1, 2017-06-19
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Serious Adverse Event (SAE) - GSK Milveterol COPD 100527
version 2, 2017-06-19
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Dose 1: GSK DTPa vaccine (Infanrix) 100484
version 1, 2017-06-19
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Non-serious Adverse Events: GSK DTPa vaccine (Infanrix) 100484
version 1, 2017-06-19
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Adverse Events Screening Visit Mepolizumab HES NCT00086658
version 1, 2017-06-11
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Adverse Events Run-In Visits Mepolizumab HES NCT00086658
version 1, 2017-06-11
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Adverse Events Day 1 Pre-Infusion Mepolizumab HES NCT00086658
version 1, 2017-06-11
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Adverse Events Day 1 Post- Infection Mepolizumab HES NCT00086658
version 1, 2017-06-11
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Adverse Events Week 1-3 Mepolizumab HES NCT00086658
version 1, 2017-06-11
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Adverse Events Week 4 Mepolizumab HES NCT00086658
version 1, 2017-06-11
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Serious Adverse Event (SAE)- Follow- Up Week 38 Mepolizumab HES NCT00086658
version 1, 2017-06-06
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Efficacy of Valtrexin in Subjects with Recurrent HSV-2 Genital Herpes Non-Serious Adverse Event
version 1, 2017-06-05
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Non-Serious Adverse Events Mepolizumab HES NCT00086658
version 1, 2017-06-05
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Efficacy of Valtrexin in Subjects with Recurrent HSV-2 Genital Herpes Serious Adverse Event
version 1, 2017-06-05
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
Serious Adverse Events Mepolizumab HES NCT00086658
version 1, 2017-06-05
  • Global rating average: 0.0 out of 5
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
ADVERSE EVENTS Roche H0650g Breast Cancer
version 1, 2017-05-29
! '← Previous' 1 3 4 5 6 7 8